# Session 2 — accepted offline reconciliation checkpoint

**PASS for the bounded offline medicine-matching/quantity services and standalone comparison consumer.** Independently re-inspected on 12 November 2026 (Asia/Calcutta).

This supersedes the changes-required decision in `SESSION_2_INDEPENDENT_REVIEW.md`. The original failures remain documented. Session 3 has not started. The running case page/API has not acquired this feature yet.

## 1. Actual verification

| Gate | Observed result |
|---|---|
| Quantity builder tests | 8/8 pass |
| Reconciliation builder tests | 35/35 pass |
| GPT backend acceptance | 56/56 pass |
| GPT consumer/rendering checks | 39/39 pass |
| Foundation regression | 125/125 pass: 35 builder, 31 adapter, 59 fixture checks |
| JSON Schema compilation | 11/11 valid |
| Both backend service syntax checks | Exit 0 |
| New reconciliation consumer's scoped strict type check | Exit 0 |
| Frozen Session 1 adapter/schema/dataset fingerprints | All unchanged |

The original 55 independent backend checks passed unchanged. GPT added one further independently authored non-suppression control: an uncertain invoice name must not suppress a supported strength difference on a reliable sibling pair, including that difference's source references. It passes, bringing the suite to 56.

The real engine-to-consumer bridge covers all 24 development scenarios and passes. This checks consumable output/context/reference integrity; it is not a held-out performance score or a browser/API integration test. No tests or warnings were skipped to obtain this checkpoint.

## 2. Corrected uncertainty policy

Exact catalogue spelling does not establish confirmed identity when the medicine-name field still needs correction. The engine now marks such identities, and label/attribute conflicts, unresolved for the missing/extra inference gate. Counterpart ambiguity also prevents a definite omission/extra verdict.

Both reproduced failures are corrected:

- An uncertain invoice name no longer proves which prescribed item is absent.
- An uncertain prescription name no longer proves which invoice item is extra.

Independently supported differences remain visible alongside uncertainty. This is not a blanket instruction to suppress all mismatches whenever any field needs correction.

The engine may retain a provisional generic label/candidate association for inspection, with the identity check marked insufficient. A `genericName` string alone is not proof of a resolved medicine. Future API/chat consumers must use the check/status/review metadata; they must not promote a provisional label to verified identity or use it for unsupported clinical answers.

## 3. Accepted interface

```js
reconcileMedicineDocuments({ caseId, prescription, invoice, catalogue })
normalizeItemQuantity(item)
```

Both functions are synchronous, offline and non-mutating. The main matcher validates the authorised server-loaded Session 1 envelopes and rejects malformed/foreign context with generic `INVALID_RECONCILIATION_INPUT` errors. IDs and catalogue data do not grant access; future routes must perform their own user/case/tenant checks before loading records.

Internal result schema: `contracts/schemas/medicine-reconciliation.schema.json`.

- Schema version: `2.0.0-session2`.
- Ruleset: `academic-reconciliation/1.0.0`.
- Outcomes: CONSISTENT, MISMATCH, INSUFFICIENT_EVIDENCE.
- Up to three items per prescription/invoice, six comparison rows.
- Base units: tablet, capsule, mL. Explicit strip/pack contents may be normalised within the documented numeric bounds.
- Mandatory `humanDecisionRequired: true`; no lifecycle, treatment, reimbursement or payment action follows automatically.
- Confirmed differences and incomplete evidence can coexist. Source references belong to the actual row's fields and documents.

The exact DTO, reasons and administrative rules remain in `SESSION_2_CONTRACT.md` and the shared schema; no schema delta was needed for the correction. `SESSION_2_CONTRACT_FREEZE.json` records the reviewed service, catalogue, schema, consumer and dataset-lock fingerprints. This is a traceable baseline, not a filesystem lock or immutable deployment. Recheck it before integration; review any semantic contract change explicitly.

## 4. What is still not implemented/accepted

- HTTP/controller/orchestrator wiring and protected result delivery.
- OCR grouping for multiple medicines, persistence of trusted grouping and grouping/correction endpoints.
- Mounting the comparison panel on the live case page or testing evidence opening in a browser.
- Integrating comparison findings with authorised human-review actions/audit/lifecycle behaviour.
- Split invoices/fills, combination-product equivalence, arbitrary medicine coverage, concentration conversions, treatment-derived quantities or clinical suitability.
- Held-out research evaluation, production/mobile acceptance or repaired app-wide type debt.

The earlier 98 application-wide TypeScript diagnostics were not repaired or re-certified by this backend re-inspection. Only the scoped consumer check was rerun here. The small academic catalogue is not a national drug database or regulatory certification.

## 5. Handoff

Session 2 is closed for its standalone scope. On student input `3`, proceed to completeness/correction/human-review integration under a new bounded ownership agreement. Do not bypass access controls, accept client-supplied authoritative grouping or turn a successful comparison into an automatic claim decision.

GPT added only its final acceptance test and checkpoint documentation in this re-inspection. Gemini-owned service code, the shared schema/component, frozen Foundation files, packages, environment and local data were not changed by GPT. No commit, push or deployment was made.
